Abstract

EE423 The Cost Savings Potential Associated with the Use of Nefecon for Adults with Primary IgA Nephropathy in the United States

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call